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publications are not available. With respect to the progress of benefit assessment and 
the subsequent price negotiation it would be helpful having alternatives with accept-
able properties in order to estimate the extent of additional benefit.
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Objectives: To use consensus-building methodologies to prioritize disease 
states for intravenous immunoglobulin (IVIG) utilization while considering dis-
ease severity and alternative therapeutic options. MethOds: A 7-member expert 
panel independently ranked 50 disease states across 2 domains: (1) Disease sever-
ity (DS) (1= immediately life-threatening, 2= life-threatening, 3= life-modifying, 
4= other) and (2) the perceived efficacy of therapeutic alternatives (TA) (1= none, 
2= low, 3= medium, 4= high). An interquartile deviation of ≤ 0.5 was used to deter-
mine consensus for disease states within each domain. Disease states reaching 
consensus across both domains were ranked according to a 4x4 algorithmic scale 
to establish priority. Results: The panel reached consensus on the severity of all 
diseases states; however, 11 of the 50 disease states did not reach consensus on 
the availability of alternative therapeutic options. No disease state was designated 
as being immediately life-threatening without an available alternative therapeu-
tic option (DS1TA1), while 3 disease states (X-linked agammaglobulinemia, com-
mon variable immunodeficiency, primary immunodeficiency with absent B-cells) 
were designated as life-threatening with no therapeutic alternatives (DS2TA1). The 
priority distribution of disorders based on the algorithm is as follows: DS1TA1= 0, 
DS1TA2= 1, DS1TA3= 1, DS1TA4= 1 DS2TA1= 3, DS2TA2= 4, DS2TA3= 3, DS2TA4= 1 
DS3TA1= 0, DS3TA2= 7, DS3TA3= 14, DS3TA4= 0 DS4TA1= 0, DS4TA2= 0, DS4TA3= 3, 
DS4TA4= 1 cOnclusiOns: The application of interquartile deviation in establishing 
consensus across two 4-point Likert scales resulted in prioritizing 80% of disease 
states where IVIG can be used. Additional consensus-building rounds will be needed 
to prioritize the remaining disease states.
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Objectives: Network meta-analysis (NMA) represents an important and develop-
ing method for Health Technology Assessment (HTA). The aim of this study was 
to review submission guidelines issued by HTA bodies worldwide and produce 
a checklist for reporting NMA within HTA submissions globally. MethOds: The 
web-based repository of country-specific pharmacoeconomic guidelines maintained 
by ISPOR was reviewed in January 2015. Guidelines from a number of countries 
providing sufficient guidance for the use of NMA in HTA submissions were iden-
tified and independently reviewed. Results: Following review of the available 
guidance from a number of countries, a single common checklist was developed. 
The checklist included recommendations relating to five main themes: data; sta-
tistical methodology; analyses performed; presentation of results; and technical 
issues. cOnclusiOns: This reporting checklist provides practical support to health 
technology manufacturers enabling them to assess the suitability of NMA reports 
in meeting the requirements of global HTA bodies. In addition, this checklist can be 
seen as a valid quality tool to critically appraise the reporting of NMAs within HTA.
ReseaRCh on MeThoDs – study Design
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Objectives: Systematic reviews (SRs) form an important part of National Institute 
for Health and Care Excellence (NICE) single technology appraisal (STA) manufac-
turer submissions. To minimise publication bias when conducting SRs, supple-
mentary searches should be conducted, and should follow the same principles 
of transparency and reproducibility as database searches. This study aimed to 
evaluate supplementary search methods used in NICE STA manufacturer submis-
sions. MethOds: NICE STAs published between 2011 and 2015 were reviewed. 
Supplementary search details from manufacturer submissions and related critique 
from corresponding evidence review group (ERG) reports were extracted. Searches 
were deemed reproducible if the minimum amount of information required to repro-
duce searches was reported. Results: Of 126 STAs identified, 80 were excluded: 
appraisal reviews/updates (n= 20); appraisal terminated (n= 12); no full submission 
available (n= 9); appendices (containing search methods) not published online 
(n= 39). Of 46 included manufacturer submissions, 28 reported conference searches, 
of which 24 provided enough information for searches to be reproduced. Twenty-one 
reported clinical trials registry searches, but only seven provided enough informa-
tion to reproduce these. Thirty-six reported conducting other manual searches, 
including: manufacturer internal databases (n= 24); reference lists (n= 20); regulatory 
body websites (n= 11); other websites (n= 5); internal experts (n= 2). Evidence review 
groups critiqued omission of supplementary searches in 8 of 18 submissions which 
lacked searches of conference proceedings, and in 8 of 25 submissions which did not 
report searching clinical trial registries. The evaluation methods differed between 
ERGs. cOnclusiOns: Principles of transparency and reproducibility were not fol-
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Objectives: Propensity Score Matching (PSM) is a common method in many 
retrospective studies to control for differential treatments. PSM controls for vari-
ables where patients are selected for one treatment over another based on aspects 
of their care that are unknown to the researcher or not a part of the study. This 
study uses simulated data comparing two cohorts within a population treated 
for a common psychiatric disorder. Data are analyzed to determine if regression 
artifacts (RA) are present in the data, uncontrolled by PSM. RA in this context are 
Type I errors. MethOds: Variables commonly used to diagnose patients with 
Major Depression were simulated: Age, Gender, Ethnicity, Global Assessment of 
Functioning, Beck Depression and Beck Anxiety scores. Distributions of N= 100,000 
were simulated for each variable using population values. From these distribu-
tions, samples of n= 100, n= 250 and n= 500 were drawn based on typical values 
that would be seen in a patient with Major Depression. The outcome measure 
Dependent Variable was the score on the Beck Depression scale, using success of 
treatment values from 10-15 percent, and correlated with the pretest score using 
Chomsky’s decomposition. PSM was used on a ratio of 1:1. Analysis methods were 
group and paired t-tests as well as a difference in difference analysis at the end of 
the study. Results: Type I error occurred in each simulation and were correlated 
with sample size. RA, leading to Type I error were more common at lower sample 
sizes, in excess of 70%, to a minimum of 54% for n= 500. cOnclusiOns: This study 
demonstrates that RA occur in basic experiments designed to specify treatment 
effects. Researchers who use PSM methods need to be aware of situations where 
RA are likely to occur. Standard statistical controls for RA are being tested to see if 
they correct for RA and Type I error when PSM is used.
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Objectives: When conducting frequentist (fixed effects or random effects) network 
meta-analysis (NMA), input data is usually required in contrast form. In practice, 
multiple-arm trials are quite common and results for only the contrast relative to 
one treatment group are presented. However, some frequentist NMA require all 
possible pairwise treatment effects and standard errors combinations. While the 
missing effect sizes can still be directly derived, additional assumptions about co-
variances are needed to calculate standard errors. MethOds: Simple imputation 
techniques are used for substituting the standard errors of the missing comparisons 
and this has been applied to both simulated data as well as a real world data exam-
ple. After imputation data is analyzed using standard frequentist NMA, incorporat-
ing multi arm studies by the method described in Rücker (2015). Results: We derive 
simple imputations techniques by (1) assuming independence between contrasts, 
(2) estimating missing co-variances from the available contrasts in the multi arm 
trials and (3) from the other two arm studies in the network. Comparable results 
to networks including all pairwise contrasts can be obtained, especially if only few 
contrasts are missing in multi arm studies and if variances of the comparisons are 
not too different. In the first case, even (1) can give acceptable results. If variances 
differ, but are similar to that from two arm studies then (3) might be preferable over 
(2). cOnclusiOns: Our results suggests that from a practical point of view, simple 
imputation techniques might be useful tools for incorporating multi arm trials with 
incomplete pairwise contrasts into frequentist NMA, although limitations need to 
be carefully considered. Rücker G: Network meta-analysis, electrical networks and 
graph theory. Research Synthesis Methods, 2012, 3, 312–324.
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Objectives: With the Act on the Reform of the Market for Medicinal Products 
(AMNOG) in Germany, pharmaceutical entrepreneurs must submit a dossier dem-
onstrating additional benefit of a new drug compared to an appropriate comparator. 
Underlying evidence was planned for registration purposes and therefore often does 
not meet the appropriate comparator as defined by the Federal Joint Committee 
(G-BA). For this reason AMNOG allows indirect comparisons (ICs) to assess the 
extent of additional benefit. This study evaluates the applicability of available IC 
methods in several situations common to benefit assessment in oncological indi-
cations. MethOds: An extensive literature search on available statistical methods 
for performing ICs is performed. Additionally, benefit dossiers containing ICs are 
analyzed regarding the applied methodology. We use simulation studies to evaluate 
and compare adjusted (Bucher) and unadjusted methods regarding their properties 
under different circumstances. Results: Adjusted ICs are deemed to be “state of the 
art”. Due to their requirements they are, nevertheless, often not applicable. In most 
cases reasons are lacking comparability of the trials, e.g. concerning the common 
comparator, the study population and the study design.Simulations of Hazard Ratios 
for endpoints overall survival and progression free survival were performed consider-
ing various “extents of additional benefit” according to IQWiG criteria. Starting with a 
setting of identical studies we stepwise modified study population and various attrib-
utes in study design. Finally the common comparator was omitted. Discrepancies 
between ICs and true values are compared graphically and on the basis of statistical 
measures. cOnclusiOns: ICs imply a set of requirements to be able to derive valid 
statements. Prerequisites for adjusted ICs are often not met as necessary studies and 
